Publications by authors named "Kathrine Aarup"
An increased risk of developing atrial fibrillation (AF) has been observed in patients with chronic lymphocytic leukemia (CLL) who were treated with ibrutinib and other BTK inhibitors. Previous studies have explored the prevalence of AF in CLL and the risk of developing AF at time of diagnosis. However, the interaction between treatment type with other risk factors on risk of developing atrial fibrillation at the time of treatment initiation has not been investigated.
View Article and Find Full Text PDFArticle Synopsis
- This study assesses the effectiveness of targeted drug treatments for chronic lymphocytic leukaemia (CLL) in a Danish cohort, comparing them to traditional chemotherapy.
- Results show that patients receiving targeted treatments, like ibrutinib and venetoclax, had a significantly better treatment-free survival (TFS) and overall survival (OS) compared to those on older chemotherapy regimens.
- Adverse events (AEs) were common in all treatment groups, but targeted therapies had a higher incidence of severe AEs, indicating the need for careful patient management.
Purpose: aberration ( mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). Although each aberration is considered an equal prognosticator, the prognostic value of carrying isolated (single-hit) or multiple (multi-hit) aberrations remains unclear, particularly in the context of targeted agents.
Patients And Methods: We performed deep sequencing of using baseline samples collected from 51 aberrant patients treated with ibrutinib in a phase II study (NCT01500733).
Unlabelled: Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited.
Objectives: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials.